Acrux (ACR) AI Stock Analysis

• Market Cap: AU$5.32M
• Dividend Yield: N/A
• Average Volume (3M): 289.48K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.01
• Revenue Growth: -76.63%
• EPS Growth: 12.00%
• Country: AU
• Employees: 43
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 409,263,520
• 10 Day Avg. Volume: 255,231
• 30 Day Avg. Volume: 289,475
• PEG Ratio: 0.06
• Price to Book (P/B): 5.51
• Price to Sales (P/S): 4.73
• P/FCF Ratio: -1.03
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 40 Underperform
• Price Target: AU$0.00 ▼(-100.00% Downside)

Acrux's overall stock score is primarily impacted by its poor financial performance and valuation metrics. The company's high leverage, persistent losses, and negative cash flows are significant concerns. Technical analysis also indicates bearish momentum, further weighing down the score. Without positive earnings call insights or corporate events to offset these issues, the stock remains a high-risk investment.

Acrux Business Overview & Revenue Model

Company Description

Acrux Limited (ACR) is a biopharmaceutical company based in Australia, specializing in the development and commercialization of innovative drug delivery technologies and pharmaceutical products. The company operates primarily in the healthcare sector, focusing on transdermal delivery systems, which enable medications to be absorbed through the skin. Acrux's core products include various transdermal patches and formulations designed to improve patient adherence and therapeutic outcomes in areas such as hormone replacement therapy and pain management.

How the Company Makes Money

Acrux generates revenue through the commercialization of its proprietary drug delivery technologies and products. The company earns money by selling its transdermal patches directly to pharmaceutical partners and healthcare providers, as well as by licensing its technologies to other companies for the development of new products. Key revenue streams include product sales, licensing agreements, and royalties from partnered products that utilize Acrux's technology. Strategic partnerships with established pharmaceutical companies enhance Acrux's market reach and provide additional revenue opportunities through collaborative development and marketing efforts.

Acrux Financial Statement Overview

Summary

Acrux Limited faces significant financial challenges, with declining revenue and negative profitability margins. Increased leverage and negative cash flows further highlight its financial instability.

Income Statement

Acrux Limited has experienced a significant decline in revenue from 2023 to 2024, with Total Revenue dropping by approximately 39.63%. The Gross Profit Margin remains negative, indicating the company is incurring costs greater than its revenue. The Net Profit Margin is also negative, reflecting consistent net losses. EBIT and EBITDA margins are unfavorable, further highlighting operational inefficiencies.

Balance Sheet

The company's Debt-to-Equity Ratio has increased, indicating higher leverage and potential financial risk. Stockholders' Equity has decreased, impacting the Equity Ratio negatively. Return on Equity is negative due to net losses, showing challenges in generating returns for shareholders. Despite these issues, the company maintains some level of cash reserves.

Cash Flow

Free Cash Flow has turned negative, showing a decline in cash generation capabilities. The Operating Cash Flow to Net Income Ratio is unfavorable, suggesting cash flow issues relative to net earnings. Free Cash Flow to Net Income is also poor, indicating challenges in converting profits into cash.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	802.00K	1.19M	5.09M	8.43M	1.72M	1.34M
Gross Profit	-1.82M	1.19M	1.13M	1.95M	-4.65M	-7.59M
EBITDA	-8.98M	-5.17M	-8.06M	-2.79M	-12.29M	-15.59M
Net Income	-5.99M	-5.95M	-5.80M	-764.00K	-9.83M	-12.63M
Balance Sheet
Total Assets	7.79M	7.22M	8.96M	14.30M	15.27M	24.20M
Cash, Cash Equivalents and Short-Term Investments	3.33M	863.00K	2.94M	6.23M	5.83M	15.27M
Total Debt	2.11M	3.63M	3.70M	2.35M	2.08M	2.23M
Total Liabilities	4.38M	6.20M	5.69M	5.60M	6.18M	5.73M
Stockholders Equity	3.41M	1.02M	3.28M	8.70M	9.09M	18.47M
Cash Flow
Free Cash Flow	-4.41M	-5.48M	-4.58M	584.00K	-9.28M	-11.52M
Operating Cash Flow	-4.27M	-5.47M	-4.30M	703.00K	-8.82M	-11.41M
Investing Cash Flow	-143.00K	-5.00K	-276.00K	-119.00K	-465.00K	-102.00K
Financing Cash Flow	3.17M	3.39M	1.29M	-183.00K	-155.00K	17.58M

Acrux Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ACR, the sentiment is Neutral. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.55 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:ACR.

Acrux Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IXC	―	AU$9.77M	-20.63	-8.72%	―	―	71.10%
NSB	―	AU$44.90M	-10.71	-16.65%	―	―	-672.73%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CHM	―	AU$10.93M	―	-469.35%	―	―	46.28%
ACR	―	AU$5.32M	―	-270.27%	―	-76.63%	12.00%
MEM	―	AU$10.46M	―	-90.15%	―	-93.83%	20.00%

Acrux Corporate Events

Acrux Limited Announces Key Resolutions for Upcoming AGM

Acrux Limited has announced its Annual General Meeting (AGM) scheduled for November 25, 2025, where shareholders will discuss key resolutions including the re-election of Dr. Geoff Brooke as a director, the issuance of rights to non-executive directors, and options to the CEO under the company’s Omnibus Equity Plan. Additionally, shareholders will consider approving a 10% placement capacity for equity securities, which could impact the company’s capital structure and shareholder value.

Acrux Announces AGM Date and Director Nominations Deadline

Acrux Limited has announced the date for its upcoming Annual General Meeting (AGM), scheduled for November 25, 2025, in Melbourne. A key agenda item will be the election of directors, with nominations accepted until October 10, 2025. This meeting is significant for stakeholders as it will shape the company’s leadership and potentially influence its strategic direction.

Acrux Secures $3.04 Million R&D Tax Rebate for FY25

Acrux Limited has received a $3.04 million R&D Tax Incentive rebate from the Australian Tax Office for FY25, which has allowed them to repay their short-term funding facility from Radium Capital. This rebate underscores Acrux’s commitment to investing in research and development in Australia, aligning with the government’s vision of fostering a future driven by Australian science.

Acrux Ltd Releases Corporate Governance Statement for FY 2025

Acrux Ltd has released its Appendix 4G and Corporate Governance Statement for the financial year ending June 30, 2025. This release, approved by the Board of Directors, highlights the company’s adherence to ASX Corporate Governance Council’s principles and recommendations, reflecting its commitment to transparency and regulatory compliance.

Acrux Expands into Saudi Market with Servacure Partnership

Acrux Limited has entered into a Sales, Marketing, Distribution, and License Agreement with Servacure Trading W.L.L. for its Dapsone 5% Gel in Saudi Arabia. This partnership marks Acrux’s strategic geographic expansion, leveraging its US FDA approvals to penetrate new markets and enhance returns on existing investments. The agreement with Servacure, which spans ten years with renewal options, involves Servacure handling regulatory approvals and manufacturing coordination in Saudi Arabia, while paying Acrux a fixed fee per unit shipped. This move is expected to strengthen Acrux’s market presence and foster long-term relationships in the Middle East.

Acrux Transitions to Commercial Focus with New Leadership and Product Launches

Acrux has announced the commencement of John Warmbrunn as the new CEO and Managing Director, succeeding Michael Kotsanis. The company has launched three new generic topical products in the USA, including Dapsone 7.5% Gel, which is contributing to accelerated revenue growth. The company received short-term RDTI funding from Radium Capital, supporting its transition from a research-focused entity to a commercialized product portfolio. The recent product launches, including Nitroglycerin 0.4% Ointment, have shown promising market traction, and Acrux aims to leverage its FDA-compliant product development capabilities to expand its market presence.